Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crizanlizumab 5.0 mg/kg and 7.5 mg/kg versus placebo in adolescents and adults with sickle cell disease
NL-OMON59951Phase 3Completed
- Sponsor
- Novartis
- Start
- Sep 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of crizanlizumab in sickle cell disease (SCD) (3 arms), sponsored by Novartis. Primary endpoint: Annualized rate of vaso-occlusive crisis events leading to healthcare visit. Started Sep 2019; status: completed.
02
Drugs
crizanlizumab
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NL-OMON59951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59951.